Comparable stake leader
MAVERICK CAPITAL LTD
SEC ownership of ROCKET PHARMACEUTICALS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001281895.
Disclosed value leader
Roderick Wong
Comparable rows
50/50
Latest evidence
21 May 2026
- Public ticker
- RCKT, RCKTW on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
MAVERICK CAPITAL LTD
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
MAVERICK CAPITAL LTD
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
21 May 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001281895
- Issuer location
- New York, NY
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ROCKET PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
MAVERICK CAPITAL LTD
Disclosed value leader
Roderick Wong
Comparable rows
50/50
Latest evidence
21 May 2026
13F
13D/G
3/4/5
Lead comparable stake: 2.3%
13D/G row: MAVERICK CAPITAL LTD
Showing 1-8 of 50 holder rows.
Quick read
MAVERICK CAPITAL LTD leads the comparable SEC ownership view at 2.3%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens MAVERICK CAPITAL LTD's linked filing trail.
Comparable ownership
Top 5
MAVERICK CAPITAL LTD
2.3%
WELLINGTON MANAGEMENT GROUP LLP
0.9%
Roderick Wong
17%
Gaurav Shah
1.3%
David P. Southwell
0.13%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| MAVERICK CAPITAL LTD |
13F
13D/G
Company
|
2.3%
from 13D/G
|
$12,771,192
3,567,372 shares
|
— | 31 Mar 2026 |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
|
0.9%
|
$7,895,181
1,004,476 shares
|
-$48,317,346 | 30 May 2025 |
| Roderick Wong |
3/4/5
Director, 10%+ Owner
|
17%
|
$44,689,444
18,236,124 shares
|
— | 18 Jun 2025 |
| Gaurav Shah |
3/4/5
CEO
|
1.3%
|
$8,390,720
1,467,962 shares
mixed-class rows
|
-$268,323 | 21 May 2026 |
| David P. Southwell |
3/4/5
Director
|
0.13%
|
$354,806
144,784 shares
|
— | 18 Jun 2025 |
| Pedro P. Granadillo |
3/4/5
Director
|
0.05%
|
$134,131
54,734 shares
|
— | 18 Jun 2025 |
| Peter Fong |
3/4/5
Director
|
0.05%
|
$174,932
53,333 shares
|
— | 24 Sep 2025 |
| Elisabeth Bjork |
3/4/5
Director
|
0.05%
|
$172,000
50,000 shares
|
+$68,500 | 02 Jan 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$589,015.
Buys
$68,500
Insiders: 1
Sells
$657,515
Insiders: 6
Net
-$589,015
Shares: -177,912
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 20,000
Shares: 197,912
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 83,733 | $0 | $275,035 | -$275,035 |
| 3-6 | 0 | 36,781 | $0 | $122,040 | -$122,040 |
| 6-9 | 10,000 | 40,471 | $34,400 | $149,044 | -$114,644 |
| 9-12 | 10,000 | 36,927 | $34,100 | $111,396 | -$77,296 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 24 reporting-owner rows connected to ROCKET PHARMACEUTICALS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
24
Largest Forms 3/4/5 holder
RTW INVESTMENTS, LP
Net 12M change
-$589,016
Latest report
26 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | Director, Other*, 10%+ Owner | $100,686,510 | Mixed | 19 Sep 2025 | ||
| Roderick Wong | Director, 10%+ Owner | $44,689,444 | Mixed | 18 Jun 2025 | ||
| Gaurav Shah | Ceo | $8,390,720 | -$268,323 | -3.1% | Mixed | 21 May 2026 |
| Kinnari Patel | President, Head of R&D and Chief Operating Officer | $6,417,297 | Mixed | 20 May 2025 | ||
| Martin Louis Wilson | General Counsel | $4,068,438 | -$105,596 | -2.5% | Mixed | 19 May 2026 |
| Jonathan David Schwartz | Chief Science & Gene Therapy Officer | $2,692,124 | -$48,848 | -1.8% | Mixed | 18 Nov 2025 |
| Gotham Makker | Director | $2,545,450 | Mixed | 18 Jun 2025 | ||
| Aaron Ondrey | Chief Financial Officer | $2,394,410 | -$4,257 | -0.18% | Mixed | 03 Jul 2025 |
| Christopher James Stevens | Chief Operating Officer | $1,782,690 | Mixed | 11 Feb 2026 | ||
| Mark Andrew White | General Manager, Commercial Affairs | $1,560,177 | Mixed | 31 Oct 2024 | ||
| Syed Ali-Aamir Rizvi | Chief Medical Officer | $1,549,921 | Mixed | 11 Feb 2026 | ||
| Carlos Garcia-Parada | Chief Financial Officer | $1,068,080 | Mixed | 14 Feb 2022 | ||
| Sarbani Chaudhuri | Chief Commercial & Medical Affairs Officer | $1,026,703 | -$67,741 | -6.2% | Filing P/S | 07 May 2026 |
| John Militello | Vice President of Finance, Treasurer, Principal Accounting Officer | $720,593 | -$162,751 | -18% | Mixed | 26 May 2026 |
| Mikael Dolsten | Director | $454,105 | Mixed | 18 Jun 2025 | ||
| Piratip Pratumsuwan | Director | $411,061 | Mixed | 18 Jun 2025 | ||
| Keith Woods | Director | $360,118 | Mixed | 13 Jun 2024 | ||
| David P. Southwell | Director | $354,806 | Mixed | 18 Jun 2025 | ||
| Peter Fong | Director | $174,932 | Mixed | 24 Sep 2025 | ||
| Elisabeth Bjork | Director | $172,000 | +$68,500 | +66% | Filing P/S | 02 Jan 2026 |
Recent insider transactions for ROCKET PHARMACEUTICALS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| John Militello | RCKT | Stock Option (Right to Buy) | Award | 116,562 | 51,509 | 26 May 2026 | Direct | |||
| John Militello | RCKT | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -238,256 | 0 | 26 May 2026 | Direct | ||
| Gaurav Shah | RCKT | Common Stock | Sale | -4.98% | $171,841 | $3.09 | -55,684 | 1,061,724 | 21 May 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Options Exercise | 7.35% | 76,490 | 1,117,408 | 21 May 2026 | Direct | ||
| Gaurav Shah | RCKT | Stock Option (Right to Buy) | Options Exercise | -100% | -76,490 | 0 | 21 May 2026 | Direct | ||
| Gaurav Shah | RCKT | Common Stock | Sale | -0.23% | $7,261 | $3.01 | -2,409 | 1,040,918 | 19 May 2026 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.1% | $1,995 | $3.01 | -662 | 677,977 | 19 May 2026 | Direct |
| John Militello | RCKT | Common Stock | Sale | -0.43% | $1,157 | $3.01 | -384 | 89,780 | 19 May 2026 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.49% | $12,120 | $3.61 | -3,361 | 678,639 | 13 May 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Sale | -0.26% | $9,837 | $3.61 | -2,728 | 1,043,327 | 13 May 2026 | Direct |
| John Militello | RCKT | Common Stock | Sale | -0.94% | $3,083 | $3.61 | -855 | 90,164 | 13 May 2026 | Direct |
| Sarbani Chaudhuri | RCKT | Common Stock | Sale | -6.19% | $67,741 | $3.84 | -17,650 | 267,510 | 07 May 2026 | Direct |
| John Militello | RCKT | Common Stock | Sale | -1.26% | $3,862 | $3.34 | -1,157 | 91,019 | 18 Feb 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Sale | -0.57% | $19,995 | $3.34 | -5,990 | 1,046,055 | 18 Feb 2026 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.2% | $4,593 | $3.34 | -1,376 | 682,000 | 18 Feb 2026 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -1.76% | $40,582 | $3.31 | -12,253 | 683,376 | 13 Feb 2026 | Direct |
| John Militello | RCKT | Common Stock | Sale | -3.89% | $12,341 | $3.31 | -3,726 | 92,176 | 13 Feb 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Sale | -1.15% | $40,668 | $3.31 | -12,279 | 1,052,045 | 13 Feb 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Award | 36.8% | 286,028 | 1,064,324 | 11 Feb 2026 | Direct | ||
| Gaurav Shah | RCKT | Stock Option (Right to Buy) | Award | 870,648 | 870,648 | 11 Feb 2026 | Direct | |||
| John Militello | RCKT | Common Stock | Award | 45.5% | 29,982 | 95,902 | 11 Feb 2026 | Direct | ||
| John Militello | RCKT | Stock Option (Right to Buy) | Award | 45,018 | 45,018 | 11 Feb 2026 | Direct | |||
| Martin Louis Wilson | RCKT | Common Stock | Award | 81.2% | 311,813 | 695,629 | 11 Feb 2026 | Direct | ||
| Martin Louis Wilson | RCKT | Stock Option (Right to Buy) | Award | 468,187 | 468,187 | 11 Feb 2026 | Direct | |||
| Syed Ali-Aamir Rizvi | RCKT | Common Stock | Award | 17.9% | 61,963 | 407,874 | 11 Feb 2026 | Direct | ||
| Syed Ali-Aamir Rizvi | RCKT | Stock Option (right to buy) | Award | 93,037 | 93,037 | 11 Feb 2026 | Direct | |||
| Christopher James Stevens | RCKT | Common Stock | Award | 15.2% | 61,963 | 469,129 | 11 Feb 2026 | Direct | ||
| Christopher James Stevens | RCKT | Stock Option (Right to Buy) | Award | 93,037 | 93,037 | 11 Feb 2026 | Direct | |||
| Sarbani Chaudhuri | RCKT | Common Stock | Award | 79.1% | 125,924 | 285,160 | 11 Feb 2026 | Direct | ||
| Sarbani Chaudhuri | RCKT | Stock Option (Right to Buy) | Award | 189,076 | 189,076 | 11 Feb 2026 | Direct | |||
| Elisabeth Bjork | RCKT | Common Stock | Purchase | 25% | $34,400 | $3.44 | 10,000 | 50,000 | 02 Jan 2026 | Direct |
| Jonathan David Schwartz | RCKT | Common Stock | Sale | -0.84% | $7,592 | $2.98 | -2,545 | 299,064 | 18 Nov 2025 | Direct |
| John Militello | RCKT | Common Stock | Sale | -1.62% | $3,240 | $2.98 | -1,086 | 65,920 | 18 Nov 2025 | Direct |
| Gaurav Shah | RCKT | Common Stock | Sale | -0.8% | $18,721 | $2.98 | -6,276 | 778,296 | 18 Nov 2025 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.43% | $4,910 | $2.98 | -1,646 | 383,816 | 18 Nov 2025 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Award | 35% | 100,000 | 385,462 | 03 Nov 2025 | Direct | ||
| John Militello | RCKT | Common Stock | Sale | -30.2% | $114,581 | $3.96 | -28,918 | 67,006 | 14 Oct 2025 | Direct |
| Syed Ali-Aamir Rizvi | RCKT | Common Stock | Award | 345,911 | 345,911 | 06 Oct 2025 | Direct | |||
| Syed Ali-Aamir Rizvi | RCKT | Stock Option (right to buy) | Award | 383,854 | 383,854 | 06 Oct 2025 | Direct | |||
| Peter Fong | RCKT | Common Stock | Award | 53,333 | 53,333 | 24 Sep 2025 | Direct | |||
| Rtw Investments, Lp | RCKT | Common Stock | Other | -5.7% | -1,100,000 | 18,188,457 | 19 Sep 2025 | See footnote | ||
| Rtw Investments, Lp | RCKT | Common Stock | Exercise of in-the-money or at-the-money derivative security | 6.08% | 1,100,000 | 19,188,457 | 19 Sep 2025 | See footnote | ||
| Rtw Investments, Lp | RCKT | Equity Swap (obligation to buy) | Exercise of in-the-money or at-the-money derivative security | -100% | -3 | 0 | 19 Sep 2025 | See footnote | ||
| John Militello | RCKT | Common Stock | Award | 71.5% | 40,000 | 95,924 | 08 Sep 2025 | Direct | ||
| Martin Louis Wilson | RCKT | Common Stock | Award | 110.7% | 150,000 | 285,462 | 08 Sep 2025 | Direct | ||
| Jonathan David Schwartz | RCKT | Common Stock | Award | 36.1% | 80,000 | 301,609 | 08 Sep 2025 | Direct | ||
| Elisabeth Bjork | RCKT | Common Stock | Purchase | 33.3% | $34,100 | $3.41 | 10,000 | 40,000 | 27 Aug 2025 | Direct |
| John Militello | RCKT | Common Stock | Sale | -0.64% | $1,082 | $3.00 | -361 | 55,924 | 19 Aug 2025 | Direct |
| Jonathan David Schwartz | RCKT | Common Stock | Sale | -0.36% | $2,412 | $3.00 | -805 | 221,609 | 19 Aug 2025 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.43% | $1,762 | $3.00 | -588 | 135,462 | 19 Aug 2025 | Direct |
* marks a reported price that did not pass the local price check.